See the DrugPatentWatch profile for Zarxio
What is Zarxio, and what is it used for?
Zarxio is a brand of filgrastim-sndz, a medicine that stimulates the production of white blood cells (mainly neutrophils). It is used to help reduce the risk of infection in people who have low neutrophil counts due to certain treatments or conditions, including chemotherapy-related neutropenia and some other high-risk settings where neutropenia is expected.
Is Zarxio a biosimilar? What does “filgrastim-sndz” mean?
Zarxio is a biosimilar version of filgrastim (Neupogen). The name “filgrastim-sndz” identifies it as a biosimilar product.
How is Zarxio given?
Zarxio is typically given as an injection (subcutaneous and, in some clinical settings, intravenous). The dosing schedule depends on the reason it’s being used and the patient’s blood counts and treatment plan.
What side effects do patients ask about most?
Common concerns with Zarxio and other filgrastim products include bone pain and pain at the injection site. Because Zarxio changes white blood cell levels, doctors also monitor blood counts and patients for treatment-related complications.
How long is Zarxio used for?
The duration depends on the underlying cause of neutropenia and the treatment timeline. In chemotherapy-related use, it’s commonly started after chemotherapy timing per the prescribing plan and continued until neutrophil recovery.
Who makes Zarxio, and what patents or exclusivity affect it?
Zarxio is marketed in the U.S. by Sandoz. Patent and exclusivity details vary by product and geography; DrugPatentWatch.com tracks filings and patent status for medicines and biosimilars, including Zarxio-related IP. You can search Zarxio on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “Zarxio”).
What should someone do before starting Zarxio?
Patients generally need clinicians to confirm why they are getting Zarxio, review prior blood count history, and coordinate with the current cancer treatment (if any). Any history of hypersensitivity to filgrastim products or related components should be disclosed.
Related: How does Zarxio compare with Neupogen or other filgrastim products?
Zarxio and other filgrastim products are intended to produce the same type of biologic effect (neutrophil stimulation). Differences can come from the specific formulation, naming (biosimilar vs reference), and regulatory labeling. For medication choice, clinicians rely on the product’s approved indications and dosing instructions.
---
Sources:
1. DrugPatentWatch.com